Liquidia Q3 2026 earnings

LQDA · 2026-11-10 07:00 BMO ET · 8-K on SEC · 10-Q on SEC

GAAP net loss of $236.3M driven by a $389.7M litigation charge, but adjusted EBITDA of $140.5M reflects continued operational strength.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$225.3M+314%+31%Ex. 99.1, income statement
EPS (GAAP)$-2.64$-2.60$-1.90Ex. 99.1, income statement
EPS (adjusted)$1.57$1.57$1.57Ex. 99.1, income statement
Net income$-236.3M$-232.8M$-310.9MEx. 99.1, income statement
Adj. EBITDA$140.5M$140.5M$44.2MEx. 99.1, income statement
Adj. EBITDA margin62.4%62.4%+6.2 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Product sales, net$222.7M+331%99%YUTREPIA
Service revenue, net$2.6M-4%1%Promotion Agreement terminated in Oct 2026

Margins and costs

  • Gross margin 93.8% (prior 96.9%, change -3.1 pp)
  • Operating expenses $84.3M (+170% YoY)
  • One-offs in the quarter Litigation settlement, net $389.7M; Income tax benefit $30.1M
  • Effective tax rate 12.7% (prior-year 0%, year-to-date 12.7%)
  • Non-GAAP bridge Adds back interest, tax, depreciation, amortization, stock-based compensation, and litigation settlement to GAAP net loss to arrive at Adjusted EBITDA.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$396.1M$284.2M$190.7M+39%
Product sales$222.7M$170.4M$51.7M+31%
R&D expenses$25.3M$17.2M$9.3M+171%
SG&A expenses$59.0M$57.4M$40.1M+47%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Product sales increased $171.0M YoY and $52.3M QoQ driven by higher YUTREPIA volume; service revenue decreased $0.1M YoY and $0.7M QoQ due to unfavorable gross-to-net adjustments and termination of the Promotion Agreement.
  • EPS story GAAP EPS decline driven by a $389.7M litigation charge and a $30.1M tax benefit; adjusted EPS remained flat YoY and QoQ.
  • One-off check Litigation settlement, net $389.7M (inclusive of $19,450 to related party) and Income tax benefit $30.1M.

The good

  • Adjusted EBITDA of $140.5M and margin of 62.4% for the fifth consecutive quarter of growth.
  • Cash and cash equivalents increased to $396.1M as of September 30, 2026.
  • Product sales of $222.7M, up 31% sequentially.

The bad

  • Net loss of $236.3M due to a significant litigation charge.
  • Service revenue decreased and the Promotion Agreement was terminated.
  • R&D expenses increased 171% YoY to $25.3M.
  • SG&A expenses increased 47% YoY to $59.0M.

The ugly

  • Net loss of $236.3M driven by a $389.7M litigation settlement charge.
  • YUTREPIA sales for PH-ILD were terminated following a patent ruling and settlement.

Open questions

  • How will the termination of the Promotion Agreement impact future service revenue?
  • What is the specific timing and amount of the $380.7M settlement payments to be made in 2026 and 2027?
  • How will the removal of the PH-ILD indication from YUTREPIA's label impact revenue and market share?
Full release

Liquidia (LQDA) earnings release, November 10, 2026

Liquidia Corp (LQDA) · Form 8-K, Item 2.02 · Filed · SEC filing

Liquidia Corporation Reports Third Quarter

2026 Financial Results

MORRISVILLE, N.C., November 10, 2026 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026.

The company will also host a webcast at 8:30 a.m. ET on November 10, 2026, to discuss its financial results and provide a corporate update.

Dr. Roger Jeffs, Liquidia’s Chief

Executive Officer, said: “Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin. Simultaneously, we will continue to advance a pipeline that builds on our deep understanding of inhaled treprostinil, from L606 in PAH and PH-ILD to new indications where patients have no approved options, such as SSc-RP and PH-COPD.

We are confident that YUTREPIA and L606 can meet the needs of many more patients, both today and in the years ahead, as we look to become the leading provider of inhaled prostacyclin care.”

YUTREPIA Commercial Highlights

(as of October 31, 2026, unless indicated otherwise)

Clinical Pipeline Updates

YUTREPIA

L606

Global Settlement with United Therapeutics

On October 13, 2026, Liquidia entered into a global settlement agreement with United Therapeutics Corporation (United Therapeutics), which resolved all six pending lawsuits between the companies.

The settlement followed a September 30, 2026, ruling by the U.S. District Court for the District of Delaware that certain claims of U.S. Patent No. 11,826,327, related to the treatment of PH-ILD with inhaled treprostinil, were valid and infringed. Under the settlement, YUTREPIA remains available to patients without disruption, and no patients are required to discontinue. Liquidia agreed not to appeal the ruling, has submitted a Prior Approval Supplement to remove the PH-ILD indication from YUTREPIA’s label, and has ceased promoting YUTREPIA for PH-ILD. The settlement agreement includes mutual releases without admission of liability by either party.

Under the settlement agreement, Liquidia agreed to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to other parties to resolve the antitrust litigation against

United Therapeutics related to Treprostinil Injection, which the company expects to fund from current cash and cash equivalents and ongoing sales of YUTREPIA.

Third Quarter 2026 Financial Results

Net loss for the third quarter of 2026 was $236.3 million, which includes a $389.7 million charge related to the litigation settlement. Excluding that charge, YUTREPIA sales led to Liquidia’s fifth consecutive quarter of increasing non-GAAP adjusted EBITDA, which was $140.5 million in the third quarter of 2026.

Cash and cash equivalents totaled $396.1 million as of September 30,

2026, prior to the payments pursuant to the settlement agreements, compared to $190.7 million as of December 31, 2025.

Product sales, net, were $222.7 million for the three months ended September 30, 2026, compared to $51.7 million for the three months ended September 30, 2025. We began shipping YUTREPIA to customers in the United States in June 2025, following receipt of full FDA approval for YUTREPIA in May 2025. The increase of $171.0 million was due to higher volume of YUTREPIA sales.

Service revenue, net and cost of service revenue, were $2.6 million and $0.8 million for the three months ended September 30, 2026, respectively, compared to $2.7 million and $0.9 million for the three months ended September 30, 2025, respectively, and related to the promotion agreement with Sandoz, Inc., pursuant to which we shared profits from the sales of Treprostinil Injection in the United States (the “Promotion Agreement”), which was terminated in October 2026. We will no longer generate service revenue.

Cost of product sales was $14.0 million for the three months ended September 30, 2026, compared to $2.3 million for the three months ended September 30, 2025. Cost of product sales is related to sales of YUTREPIA. The increase of $11.7 million was primarily due to higher volume of YUTREPIA sales.

Research and development expenses were $25.3 million for the three months ended September 30, 2026, compared to $9.3 million for the three months ended September 30, 2025. The increase of $16.0 million or 170% was primarily due to an $11.1 million increase in expenses for our L606 program, a $3.2 million increase in expenses related to YUTREPIA research and development activities, and a $1.2 million increase in personnel expenses driven by higher headcount.

Selling, general and administrative expenses were $59.0 million for the three months ended September 30, 2026, compared to $40.1 million for the three months ended September 30, 2025. The increase of $18.9 million or 47% was primarily due to a $6.4 million increase in personnel expenses and a $5.5 million increase in stock-based compensation driven by higher headcount, a $4.1 million increase in commercial and consulting expenses to support the commercialization of YUTREPIA.

Litigation settlement, net was $389.7 million for the three months ended September 30, 2026 and reflects charges recorded for the settlement of the litigation with United Therapeutics and.e parties with interests in the antitrust litigation against United Therapeutics related to Treprostinil Injection, consisting of $330.4 million payable to United Therapeutics, less $10.0 million receivable from United Therapeutics, $60.3 million payable to the parties with interests in the antitrust litigation against United Therapeutics related to Treprostinil Injection, and other non-cash write offs of assets related to the Promotion Agreement.

Interest expense, net was $2.9 million for the three months ended September 30, 2026, compared to $5.3 million for the three months ended September 30, 2025. The decrease of $2.4 million was primarily attributable to higher money market balances and lower interest accretion under the Company’s revenue interest financing agreement with HealthCare Royalty Partners IV, L.P.

Income tax benefit was $30.1 million for the three months ended

September 30, 2026. We did not recognize any income tax benefit during the three months ended September 30, 2025.

Net loss for the three months ended September 30, 2026, was $236.3 million, or $2.64 per basic and diluted share, as compared to a net loss of $3.5 million, or $0.04 per basic and diluted share, for the three months ended September 30, 2025.

Webcast Information

Liquidia will host a live webcast at 8:30 a.m. Eastern Time on

November 10, 2026, to discuss the third quarter 2026 financial results and corporate update. The webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.

About YUTREPIA® (treprostinil) Inhalation Powder

YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA is approved and marketed for the treatment of pulmonary arterial hypertension (PAH). YUTREPIA is not approved for the treatment of systemic sclerosis-associated

Raynaud’s phenomenon (SSc-RP); it has received Fast Track designation from the FDA for SSc-RP. YUTREPIA was previously referred to as LIQ861 in investigational studies.

About L606 (liposomal treprostinil inhalation suspension)

L606 is an investigational, extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. The L606 suspension uses a proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time. L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD and is being evaluated in Re-Spire, a global pivotal placebo-controlled efficacy study to evaluate L606 in adults for the treatment of PH-ILD.

About Pulmonary Arterial Hypertension

(PAH)

PAH is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, more than 50,000 estimated patients are diagnosed and treated in the United

States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression and improve quality of life.

About Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

PH-ILD includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease-related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor 3-year survival. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though actual prevalence in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021 when inhaled treprostinil was first approved for this indication.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, approved for the treatment of pulmonary arterial hypertension (PAH), and in development for Raynaud’s phenomenon secondary to systemic sclerosis (SSc-RP). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily via a next-generation nebulizer to treat PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

To learn more about Liquidia, please visit www.liquidia.com.

Abbreviations

Financial statements

Income Statement

Three Months Ended September 30, — (in thousands, except share and per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Revenues:
Product sales, net222,74451,669
Service revenue, net2,5562,673
Total revenue225,30054,342
Costs and expenses:
Cost of product sales13,9852,295
Cost of service revenue792878
Research and development25,2699,346
Selling, general and administrative59,02440,056
Litigation settlement, net (inclusive of $19,450 to related party)389,749
Total costs and expenses488,81952,575
(Loss) income from operations-263,5191,767
Interest expense, net-2,880-5,300
Loss before income taxes-266,399-3,533
Income tax benefit-30,071
Net loss and comprehensive loss-236,328-3,533
Net loss per common share, basic and diluted-2.64-0.04
Weighted average common shares outstanding, basic and diluted89,521,46786,333,772

Income Statement

Three Months Ended — (in thousands)

Three Months Ended – September 30,2026
Net loss-236,328
Interest expense, net2,880
Income tax benefit-30,071
Depreciation and amortization545
EBITDA-262,974
Litigation settlement, net389,749
Stock-based compensation13,678
Adjusted EBITDA140,453

Balance Sheet

September 30, — Liquidia Corporation Select Consolidated Balance Sheet Data (in thousands)

September 30, – 2026December 31, – 2025
Cash and cash equivalents396,091190,680
Total assets682,942327,934
Total liabilities708,376283,186
Accumulated deficit-735,057-626,313
Total stockholders’ (deficit) equity-25,43444,748

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating activities
Net loss-108,744-83,479
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation33,26522,266
Depreciation and amortization1,4421,208
Non-cash lease expense201173
Accretion and non-cash interest expense18,79317,271
Acquired in-process research and development1,000
Changes in operating assets and liabilities:
Accounts receivable, net-52,656-33,240
Inventory-11,841-23,931
Prepaid expenses and other current assets-42,875-3,064
Other noncurrent assets-17,5461,964
Accounts payable1,167-629
Litigation settlement, net389,749
Accrued expenses and other current liabilities66,94021,785
Operating lease liabilities32-254
Other noncurrent liabilities985

1. PAH: pulmonary arterial hypertension.

2. PH-ILD: pulmonary hypertension associated with interstitial lung disease. 3. SSc-RP: systemic sclerosis-associated Raynaud’s phenomenon. 4. PH-COPD: pulmonary hypertension associated with chronic obstructive pulmonary disease.

Cautionary Statements Regarding Forward-Looking

Statements

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform

Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding... (truncated)nitiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements.

Forward-looking statements, including statements regarding the settlement agreement and its anticipated benefits; timing and outcome of FDA review of the Prior Approval Supplement to remove the PH-ILD indication from the YUTREPIA label; the impact of ceasing PH-ILD promotion and sales on YUTREPIA revenue; continued availability of YUTREPIA for patients; clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs); regulatory applications and related submission contents and timelines; our future results of operations, financial position and cash resources; our estimates regarding future expenses, capital requirements and needs for additional financing; potential revenue and profitability of YUTREPIA; and our development plans for

L606 and for YUTREPIA in SSc-RP, PH-COPD or other indications, are forward-looking statements. These statements involve significant risks and uncertainties, and actual results could differ materially from those expressed or implied herein. Among other things, the settlement agreement does not extend to indications other than PAH or to new treprostinil-containing products, and United Therapeutics may assert patents against our development programs or future products. Fast Track designation does not guarantee that YUTREPIA will receive FDA approval for the treatment of SSc-RP or that development will proceed on the anticipated timeline. The words “anticipate,”

“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”

“may,” “plan,” “potential,” “predict,” “project,” “should,” “target,”

“would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Information

This press release and the accompanying tables include U.S. Generally Accepted Accounting Principles (GAAP) and non-GAAP financial measures. For a description of such non-GAAP financial measures, including the reasons for using such measures, and reconciliations of such non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with GAAP, please see the section entitled “About Non-GAAP Financial Information” below.

Contact Information

Investors:

Jason Adair

Chief Business Officer

919.328.4350

Jason.adair@liquidia.com

Media: media@liquidia.com

Liquidia Corporation

Select Consolidated Balance Sheet Data

(in thousands)

Liquidia Corporation

Consolidated Statements of Operations and Comprehensive Income (Loss)

(unaudited)

(in thousands, except share and per share amounts)

About Non-GAAP Financial Information

To supplement our financial results presented in accordance with U.S.

Generally Accepted Accounting Principles (GAAP), this press release includes certain non-GAAP financial measures, such as Adjusted EBITDA.

We believe the use of such non-GAAP financial measures provides investors with additional insight into our operational performance. While we compute non-GAAP financial measures using a consistent method from quarter to quarter and year to year, we may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.

Adjusted EBITDA is a non-GAAP measure that represents net income for the period before the impact of interest income, interest expense, other income and expense, income taxes, depreciation and amortization, and certain items that impact comparison of the performance of our business either period-over-period or with other businesses.

Adjusted EBITDA should not be considered in isolation or as a substitute to net income or any other measure of financial performance calculated and presented in accordance with GAAP. Our calculation of

Adjusted EBITDA may not be comparable to similarly titled measures of other companies because other companies may not calculate them in the same manner as we calculate these measures.

For a reconciliation of such non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with GAAP, please see the table titled “Reconciliation of Non-GAAP

Financial Information” below.

Liquidia Corporation

Reconciliation of Non-GAAP Financial Information... (truncated)justed EBITDA

(unaudited)

(in thousands)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.